CONDITION

Degenerative Myelopathy in Dogs

A progressive neurological condition affecting the spinal cord, leading to gradual loss of coordination and strength in the hind legs.

Why this matters now

Degenerative myelopathy (DM) typically manifests in dogs between eight and fourteen years of age, most commonly emerging in the later years of a dog's life. The condition has been most extensively documented in German Shepherd Dogs, but is now recognised across a wide range of breeds including Pembroke Welsh Corgis, Boxers, Rhodesian Ridgebacks, Chesapeake Bay Retrievers, Bernese Mountain Dogs, and many others. A strong genetic basis has been established, with mutations in the superoxide dismutase 1 (SOD1) gene identified as a major risk factor — the same gene implicated in some forms of amyotrophic lateral sclerosis (ALS) in humans. Dogs that are homozygous for the mutation (carrying two copies) are at significantly elevated risk, though not all homozygous dogs develop clinical disease, suggesting that additional genetic and environmental modifiers influence expression. The condition is not painful in itself, which distinguishes it from many other causes of progressive hind limb weakness, though the resulting mobility challenges can affect quality of life as the disease advances.

Degenerative myelopathy follows a characteristic progressive course that unfolds over months to years, though the rate of progression varies considerably between individuals. The condition typically begins with subtle hind limb weakness and incoordination (ataxia), often initially noticed as scuffing of the hind paws, swaying of the hindquarters during walking, or difficulty with turns and uneven terrain. Over the subsequent months, the weakness and ataxia become more pronounced, progressing to a point where the dog may cross its hind limbs during walking, have difficulty rising from lying positions, and eventually develop paresis (partial paralysis) of the hind limbs. In the later stages, the disease can progress to complete hind limb paralysis and may eventually extend to involve the forelimbs and affect other neurological functions including faecal and urinary continence. The progression from initial signs to significant disability typically spans six to twelve months in many dogs, though some individuals progress more slowly over one to three years.

Signals & patterns

Early signals

Hind paw scuffing

One of the earliest and most commonly reported signs is the sound or evidence of the dog dragging or scuffing the tops of its hind paws during walking, which results from reduced proprioceptive awareness — the ability to sense where the feet are positioned in space. Owners may notice worn or scuffed toenails on the hind feet, or hear a distinctive scraping sound on hard surfaces. This occurs because the degenerating spinal cord tracts responsible for relaying positional information from the hind limbs to the brain are among the first to be affected, impairing the dog's ability to correctly place its feet.

Hind limb ataxia and swaying

The hindquarters may develop a noticeable sway or wobble during walking, with the dog appearing slightly unsteady or 'drunk' in its hind end, particularly when walking slowly or making turns. This general proprioceptive ataxia reflects impaired transmission of sensory information from the hind limbs through the degenerating dorsal spinal cord tracts. The ataxia tends to be most apparent on smooth or slippery surfaces, during slow turns, and when the dog is tired, and may initially be intermittent before becoming consistently present.

Crossing of hind limbs

Dogs may begin to cross or overlap their hind limbs while walking, sometimes appearing to not realise that one leg has moved into the path of the other. This 'crossing over' or 'scissoring' gait pattern is a hallmark of proprioceptive dysfunction and occurs because the dog cannot accurately gauge the position of its hind limbs relative to each other. When standing still, the dog may also place its hind feet in unusual positions — turned under (knuckling), placed too far apart, or crossed — without correcting the positioning.

Difficulty with transitions

Rising from lying or sitting positions may become noticeably more effortful, with the dog requiring multiple attempts or using its forelimbs more prominently to pull itself up rather than pushing with the hind limbs. Similarly, lying down may become less controlled, with the dog dropping its hindquarters abruptly rather than lowering itself gradually. These changes reflect the progressive loss of motor function in the hind limbs as the descending motor tracts in the lateral funiculi of the spinal cord degenerate.

Asymmetric onset

In many dogs, the early signs of degenerative myelopathy are more apparent in one hind limb than the other, which can create an impression of a unilateral orthopaedic problem rather than a neurological condition. This asymmetry may persist for weeks to months before the contralateral limb begins to show comparable changes. The initial lateralisation may reflect asymmetric progression of the degenerative process within the spinal cord, though the underlying pathology is ultimately bilateral.

Later signals

Progressive paresis to paralysis

As the disease advances, the hind limb weakness progresses from ataxia through paresis (reduced voluntary movement) to eventual paraplegia (complete loss of voluntary movement in the hind limbs). Dogs may become unable to stand or walk unassisted, and the hind limbs may be dragged during any remaining attempts at locomotion. The transition from ambulatory weakness to non-ambulatory paresis represents a significant milestone in the disease course and typically prompts reassessment of supportive care strategies and quality of life considerations.

Muscle atrophy

Progressive wasting of the muscles in the hind limbs becomes increasingly apparent as the condition advances, reflecting both disuse atrophy from reduced voluntary movement and denervation atrophy from the loss of motor nerve input to the muscles. The thigh and hip musculature may become visibly wasted, and the bony prominences of the pelvis and hind limbs may become more prominent. This muscle loss further reduces the dog's ability to support its weight on the hind limbs and contributes to the overall decline in mobility.

Loss of continence

In the later stages of the disease, some dogs develop faecal and/or urinary incontinence as the degenerative process extends to affect the spinal cord segments controlling bladder and bowel function. This may manifest as involuntary loss of urine during rest, inability to fully empty the bladder, or loss of voluntary control over defecation. The development of incontinence typically occurs after significant hind limb paresis has already been established and represents extension of the disease process to the sacral spinal cord segments.

Forelimb involvement

In dogs that survive long enough for the disease to advance to this stage, the degenerative process may extend rostrally to involve the cervical spinal cord, producing signs of forelimb weakness, ataxia, and incoordination in addition to the pre-existing hind limb paralysis. Difficulty swallowing and respiratory compromise may eventually develop in the most advanced stages, though many dogs are humanely euthanised before the disease reaches this point due to quality of life considerations related to the earlier stages of the disease.

Click to read about the biological mechanisms

How this is usually investigated

Degenerative myelopathy is currently a diagnosis of exclusion, meaning that other conditions causing similar clinical signs must be systematically ruled out before DM can be considered the most likely explanation. The investigation process typically involves neurological examination, diagnostic imaging of the spine, and often genetic testing, with the definitive diagnosis only achievable through post-mortem histopathological examination of the spinal cord.

Neurological examination

Purpose: A thorough neurological examination is essential for characterising the type and distribution of neurological deficits, which helps localise the lesion within the nervous system and differentiate DM from other conditions. The examination typically reveals upper motor neuron signs in the hind limbs — including proprioceptive deficits, spastic paresis, preserved or exaggerated spinal reflexes, and crossed extensor reflexes — while the forelimbs remain normal in the earlier stages. The pattern of deficits (bilateral, progressive, non-painful, upper motor neuron) is characteristic and helps guide the subsequent diagnostic approach.
Considerations: The neurological examination findings in DM can overlap with those of other conditions affecting the thoracolumbar spinal cord, including intervertebral disc disease, spinal cord tumours, and other myelopathies. The absence of pain on spinal palpation and manipulation, combined with the slowly progressive course and breed predisposition, may increase clinical suspicion for DM, but cannot confirm the diagnosis in isolation. Serial neurological examinations over time can help document the progressive nature of the deficits.

MRI of the spine

Purpose: Magnetic resonance imaging of the thoracolumbar spine is the primary imaging modality used to exclude other structural causes of progressive hind limb weakness and ataxia. MRI can identify compressive lesions such as intervertebral disc herniations, spinal cord tumours, vertebral malformations, and other structural abnormalities that may produce similar clinical signs. In dogs with DM, the MRI is typically unremarkable or may show only mild, non-specific changes in the spinal cord that do not adequately explain the severity of clinical signs — this discrepancy between clinical severity and imaging findings is itself suggestive of a degenerative process.
Considerations: MRI requires general anaesthesia and represents a significant financial investment, and availability may be limited to specialist veterinary centres. A normal MRI does not confirm DM — it excludes other identifiable structural causes, which is why DM remains a diagnosis of exclusion. Some dogs may have incidental findings on MRI (such as minor disc protrusions common in older dogs) that must be carefully evaluated to determine whether they are clinically significant or merely coincidental findings in a dog with underlying DM.

Cerebrospinal fluid analysis

Purpose: Analysis of cerebrospinal fluid (CSF) collected from the lumbar cistern or cerebellomedullary cistern may be performed to help exclude inflammatory, infectious, or neoplastic conditions affecting the spinal cord. In dogs with DM, the CSF analysis is typically normal or shows only very mild, non-specific elevations in protein, which helps differentiate the condition from inflammatory myelopathies (such as granulomatous meningoencephalomyelitis) or infectious conditions that typically produce more significant CSF changes.
Considerations: CSF collection carries a small risk of complications and requires general anaesthesia. The procedure is often performed in conjunction with MRI. Normal CSF results are supportive of but not diagnostic for DM, as they contribute to the exclusion of other differential diagnoses rather than providing positive confirmation. The interpretation of CSF results is most meaningful when considered alongside the neurological examination findings and imaging results.

SOD1 genetic testing

Purpose: DNA-based testing for mutations in the SOD1 gene is commercially available and can identify dogs that carry one or two copies of the mutations associated with DM. Homozygosity (two copies) for the mutation is considered a significant risk factor for developing DM, and the test result can be combined with the clinical picture and imaging findings to increase or decrease the clinical suspicion for the diagnosis. The test can be performed on blood samples or cheek swabs and does not require anaesthesia.
Considerations: A positive genetic test (homozygous for the mutation) does not confirm that a dog has DM, as not all homozygous dogs develop the clinical disease — it indicates genetic susceptibility rather than active disease. Conversely, a negative result (clear or heterozygous) makes DM considerably less likely but may not completely exclude it in all breeds, as additional SOD1 mutations may exist that are not yet identified by current testing panels. The genetic test is most informative when interpreted alongside the clinical presentation, neurological examination, and imaging findings rather than in isolation.

Post-mortem histopathology

Purpose: Definitive diagnosis of degenerative myelopathy can only be achieved through microscopic examination of the spinal cord after death, which reveals the characteristic pattern of axonal degeneration and demyelination predominantly affecting the dorsal and lateral funiculi of the thoracolumbar spinal cord. Histopathology can confirm the presence of the disease, establish its severity and distribution, and definitively exclude other conditions that may have been suspected during life. This information, while not benefiting the individual dog, can provide closure for owners, contribute to breed health research, and inform genetic counselling for related dogs.
Considerations: As a post-mortem procedure, histopathological confirmation obviously cannot guide management decisions during the dog's life. The quality and diagnostic value of the examination depend on proper tissue collection, preservation, and processing. Some owners find comfort in obtaining a definitive answer, while others may not wish to pursue post-mortem examination. Research programmes studying DM may welcome donated tissue, contributing to the broader understanding of the disease.

Options & trade-offs

There is currently no treatment that halts or reverses the progression of degenerative myelopathy, and management focuses on maintaining quality of life, supporting mobility for as long as possible, and addressing secondary complications. The approaches centre on physical rehabilitation, assistive devices, supportive care, and ongoing quality of life assessment.

Intensive physical rehabilitation

Structured physiotherapy and rehabilitation programmes represent the primary management strategy for dogs with DM, with some evidence suggesting that regular, intensive exercise and targeted physiotherapy may slow the rate of functional decline compared to dogs that receive no structured rehabilitation. Programmes typically include controlled walking (including on varied terrain), swimming or underwater treadmill therapy, balance exercises, range of motion exercises, and core strengthening activities. The intensity and composition of the programme are adapted as the dog's abilities change, with the focus shifting from active exercises in the early stages to more passive techniques as the disease progresses.

Trade-offs: Access to veterinary physiotherapists and hydrotherapy facilities varies by location, and the time commitment for daily home exercises can be substantial. The evidence for the efficacy of rehabilitation in DM, while encouraging, is primarily based on observational studies rather than large randomised controlled trials, so the expected degree of benefit is not precisely quantified. The cost of professional rehabilitation sessions accumulates over time, and the progressive nature of the disease means that the benefits are in slowing decline rather than achieving improvement. As the disease advances, some exercises may need to be discontinued, and the focus of rehabilitation shifts toward comfort and quality of life.

Assistive mobility devices

Various assistive devices can help dogs with DM maintain mobility and quality of life as hind limb function deteriorates. Hind limb harnesses and slings allow owners to support the dog's weight during walking, providing assistance with rising, navigating stairs, and outdoor toileting. Wheelchair carts (wheeled mobility devices) can allow dogs with significant hind limb paresis or paralysis to continue moving independently, exercising, and engaging with their environment. Non-slip footwear or booties can help protect paws that are dragging due to proprioceptive deficits, and non-slip mats or runners throughout the home can improve traction on smooth flooring.

Trade-offs: The suitability and acceptance of assistive devices varies between individual dogs, with some adapting readily and enthusiastically while others may resist or find them stressful. Wheelchair carts require proper fitting and adjustment, and the dog's conformation, size, and temperament influence how successfully a cart can be used. Supporting a large dog with a harness places physical demands on the owner, and the logistics of managing toileting and daily activities with increasingly limited mobility can be challenging. Skin integrity under harnesses and in areas that may contact the ground requires regular monitoring.

Environmental modifications and nursing care

Adapting the home environment and providing appropriate nursing care become increasingly important as DM progresses. Environmental modifications may include providing non-slip surfaces throughout the home, raising food and water bowls, using ramps instead of stairs, ensuring comfortable and supportive bedding, and creating easy access to outdoor toileting areas. Nursing care may involve regular position changes for recumbent dogs to prevent pressure sores, bladder management (manual expression or monitoring for urinary retention), hygiene maintenance for incontinent dogs, and skin care to prevent urine scald or dermatitis.

Trade-offs: The nursing care requirements increase progressively as the disease advances, potentially requiring significant time, physical effort, and emotional energy from owners. Pressure sores can develop rapidly in non-ambulatory dogs, particularly over bony prominences, and once established can be difficult to manage. Urinary management may require veterinary guidance to determine whether the bladder is emptying adequately, and urinary tract infections may develop in dogs with impaired bladder function. The increasing dependency of the dog on owner assistance for basic functions can be emotionally demanding, and the balance between providing supportive care and maintaining quality of life requires ongoing reassessment.

Investigational and complementary approaches

Various complementary and investigational approaches have been explored for dogs with DM, including acupuncture, laser therapy, antioxidant supplementation (including vitamin E and vitamin C), aminocaproic acid, N-acetylcysteine, and other nutraceutical or pharmacological interventions. Some owners report subjective improvement with certain complementary therapies, though the evidence base for individual modalities in DM specifically is generally limited. Research into potential disease-modifying therapies continues, with some studies investigating gene therapy, stem cell therapy, and other novel approaches in animal models.

Trade-offs: The scientific evidence supporting most complementary and investigational approaches for DM is currently insufficient to draw firm conclusions about their efficacy. Costs can accumulate when multiple supplements or therapies are combined, and the potential for placebo effect or observer bias should be considered when evaluating subjective improvements. Some dogs may find certain therapies (such as acupuncture) stressful, while others appear to tolerate them well. Participation in clinical trials, where available, may provide access to novel therapies while contributing to research, but involves specific commitments and protocols.

Common misconceptions

Misconception:

"Degenerative myelopathy is painful, and the dog's reluctance to move indicates that it is in pain."

Reality:

Degenerative myelopathy is characterised by a loss of proprioception and motor function rather than pain generation. The degenerating pathways in the spinal cord are primarily those carrying motor and positional information, not pain signals. The dog's reluctance to move or difficulty walking reflects physical inability due to weakness and incoordination rather than pain avoidance. This distinction is important because it means that pain management, while appropriate for any concurrent orthopaedic conditions, is not a primary component of DM management itself. However, secondary complications such as joint strain from abnormal gait compensations or pressure sores from recumbency may introduce discomfort that warrants attention.

Misconception:

"A positive SOD1 genetic test means the dog definitely has or will develop degenerative myelopathy."

Reality:

The SOD1 genetic test identifies a mutation that is a major risk factor for developing DM, but homozygosity for the mutation does not guarantee that a dog will develop clinical disease. Studies indicate that a significant proportion of dogs homozygous for the SOD1 mutation live their entire lives without developing clinical DM, suggesting that additional genetic, environmental, and age-related factors influence whether the disease manifests. The genetic test is most informative when interpreted in the context of the complete clinical picture — a homozygous result in a dog with compatible clinical signs strengthens the clinical suspicion for DM, while the same result in a young, neurologically normal dog is a risk indicator rather than a diagnosis.

Misconception:

"Nothing can be done for dogs with degenerative myelopathy, so there is no point in diagnosis or management."

Reality:

While there is currently no cure or treatment that reverses the spinal cord degeneration, this does not mean that nothing meaningful can be done. Structured rehabilitation programmes may help maintain function for longer, assistive devices can enable continued mobility and quality of life, and appropriate supportive care can address secondary complications. Accurate diagnosis also allows for realistic planning, appropriate adaptation of the home environment, and informed decision-making about quality of life. The distinction between 'no cure' and 'no beneficial intervention' is significant, and many dogs with DM maintain good quality of life for months with appropriate supportive management.

Living with degenerative myelopathy involves an evolving journey of adaptation as the condition progresses through its stages. Understanding the trajectory — from early subtle changes through progressive hind limb weakness to potential loss of independent mobility — can help in anticipating needs and making thoughtful decisions about support and quality of life at each stage. The absence of pain in the condition itself is a distinguishing feature, though secondary issues such as skin breakdown, urinary complications, and the emotional impact on the human-animal bond all contribute to the broader picture. Regular reassessment of how the dog experiences daily life — their engagement, comfort, dignity, and enjoyment — tends to become an increasingly important focus as the disease advances.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS